In summary, these data demonstrate that the anti-DR5 ADC, Zapadcine-1, is a very promising candidate for further exploration of its potential as a novel cancer therapeutic agent, especially for the acute lymphocyte leukemia. Here, TNFRSF10B is linked to acute lymphoblastic leukemia.